Literature DB >> 25809483

The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization.

Patrick L Leslie1, Hengming Ke2, Yanping Zhang3.   

Abstract

The oncoprotein murine double minute 2 (MDM2) is an E3 ligase that plays a prominent role in p53 suppression by promoting its polyubiquitination and proteasomal degradation. In its active form, MDM2 forms homodimers as well as heterodimers with the homologous protein murine double minute 4 (MDMX), both of which are thought to occur through their respective C-terminal RING (really interesting new gene) domains. In this study, using multiple MDM2 mutants, we show evidence suggesting that MDM2 homo- and heterodimerization occur through distinct mechanisms because MDM2 RING domain mutations that inhibit MDM2 interaction with MDMX do not affect MDM2 interaction with WT MDM2. Intriguingly, deletion of a portion of the MDM2 central acidic domain selectively inhibits interaction with MDM2 while leaving intact the ability of MDM2 to interact with MDMX and to ubiquitinate p53. Further analysis of an MDM2 C-terminal deletion mutant reveals that the C-terminal residues of MDM2 are required for both MDM2 and MDMX interaction. Collectively, our results suggest a model in which MDM2-MDMX heterodimerization requires the extreme C terminus and proper RING domain structure of MDM2, whereas MDM2 homodimerization requires the extreme C terminus and the central acidic domain of MDM2, suggesting that MDM2 homo- and heterodimers utilize distinct MDM2 domains. Our study is the first to report mutations capable of separating MDM2 homo- and heterodimerization.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  RING finger protein 4 (RNF4); cancer; enzyme mechanism; mouse double minute 2 homolog (MDM2); p53

Mesh:

Substances:

Year:  2015        PMID: 25809483      PMCID: PMC4432308          DOI: 10.1074/jbc.M115.644435

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  PUMA, a novel proapoptotic gene, is induced by p53.

Authors:  K Nakano; K H Vousden
Journal:  Mol Cell       Date:  2001-03       Impact factor: 17.970

2.  The RING domain of Mdm2 can inhibit cell proliferation.

Authors:  Jinjun Dang; Mei-Ling Kuo; Christine M Eischen; Lilia Stepanova; Charles J Sherr; Martine F Roussel
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

3.  Hypophosphorylation of Mdm2 augments p53 stability.

Authors:  Christine Blattner; Trevor Hay; David W Meek; David P Lane
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

4.  The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.

Authors:  Masha V Poyurovsky; Christina Priest; Alex Kentsis; Katherine L B Borden; Zhen-Qiang Pan; Nikola Pavletich; Carol Prives
Journal:  EMBO J       Date:  2006-12-14       Impact factor: 11.598

5.  Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.

Authors:  K Linke; P D Mace; C A Smith; D L Vaux; J Silke; C L Day
Journal:  Cell Death Differ       Date:  2008-01-25       Impact factor: 15.828

6.  ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.

Authors:  Qian Cheng; Lihong Chen; Zhenyu Li; William S Lane; Jiandong Chen
Journal:  EMBO J       Date:  2009-12-16       Impact factor: 11.598

7.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.

Authors:  J Parant; A Chavez-Reyes; N A Little; W Yan; V Reinke; A G Jochemsen; G Lozano
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

8.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Authors:  Audrey Petitjean; Ewy Mathe; Shunsuke Kato; Chikashi Ishioka; Sean V Tavtigian; Pierre Hainaut; Magali Olivier
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

9.  Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.

Authors:  Koji Itahana; Hua Mao; Aiwen Jin; Yoko Itahana; Hilary V Clegg; Mikael S Lindström; Krishna P Bhat; Virginia L Godfrey; Gerard I Evan; Yanping Zhang
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  19 in total

1.  Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.

Authors:  Hui Tian; Nicole R Tackmann; Aiwen Jin; Junnian Zheng; Yanping Zhang
Journal:  J Biol Chem       Date:  2017-11-09       Impact factor: 5.157

2.  p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.

Authors:  Ixaura Medina-Medina; Mayra Martínez-Sánchez; Jesús Hernández-Monge; Robin Fahraeus; Petr Muller; Vanesa Olivares-Illana
Journal:  Protein Sci       Date:  2018-03-25       Impact factor: 6.725

3.  Characterization of cancer-associated missense mutations in MDM2.

Authors:  Krishna M Chauhan; Gopalakrishnan Ramakrishnan; Madhusudhan Kollareddy; Luis A Martinez
Journal:  Mol Cell Oncol       Date:  2015-12-10

Review 4.  The roles of E3 ligases in Hepatocellular carcinoma.

Authors:  Zongdong Yu; Hong Li; Jie Zhu; Haibiao Wang; Xiaofeng Jin
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 5.  MDM2 oligomers: antagonizers of the guardian of the genome.

Authors:  P L Leslie; Y Zhang
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

6.  Alterations in expression levels of genes in p53-related pathways determined using RNA-Seq analysis in patients with breast cancer following CIK therapy.

Authors:  Zuowei Hu; Xiaoye Zhang; Hang Yang; Shuanglai Qin; Yaqi Liu; Wei Xiong; Bing Yuan; Liping Li; Weiqi Yao; Dongcheng Wu
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

Review 7.  TGF-β1-p53 cooperativity regulates a profibrotic genomic program in the kidney: molecular mechanisms and clinical implications.

Authors:  Craig E Higgins; Jiaqi Tang; Badar M Mian; Stephen P Higgins; Cody C Gifford; David J Conti; Kirstan K Meldrum; Rohan Samarakoon; Paul J Higgins
Journal:  FASEB J       Date:  2019-07-06       Impact factor: 5.834

8.  MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation In Vivo.

Authors:  Jing Yang; Aiwen Jin; Jing Han; Xin Chen; Junnian Zheng; Yanping Zhang
Journal:  Cancer Res       Date:  2020-12-04       Impact factor: 13.312

9.  Numb contributes to renal fibrosis by promoting tubular epithelial cell cycle arrest at G2/M.

Authors:  Fengxin Zhu; Wei Liu; Tang Li; Jiao Wan; Jianwei Tian; Zhanmei Zhou; Hao Li; Youhua Liu; Fan Fan Hou; Jing Nie
Journal:  Oncotarget       Date:  2016-05-03

Review 10.  Clinical Overview of MDM2/X-Targeted Therapies.

Authors:  Andrew Burgess; Kee Ming Chia; Sue Haupt; David Thomas; Ygal Haupt; Elgene Lim
Journal:  Front Oncol       Date:  2016-01-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.